| Predicate |
Object |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-186
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-565
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-54
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-55
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-33
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-63
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-577
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-56983
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-42
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-109 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-63
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-13
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-577
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-571
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-42 |
| filingDate |
2016-06-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2019-02-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
2019-02-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CN-107011435-B |
| titleOfInvention |
The human monoclonal antibodies 8D6 of anti-hepatitis c virus |
| abstract |
The present invention relates to the neutrality human monoclonal antibodies 8D6 of anti-hepatitis c virus.Antibody of the invention can prevent Hepatitis C Virus from infecting permissive cell in conjunction with the E2 subunit of Hepatitis C Virus.Using antibody variable gene or complementary determining region (CDR) gene of the invention, various forms of genetic engineering antibodies can be transformed and produced in any expression system using protokaryon and eukaryocyte. |
| priorityDate |
2016-06-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |